Vaccine industry must help fight monkeypox and secure supply chains
Monkeypox is unlikely to develop into another pandemic, according to the WHO. But the recent spread of the virus could still be a challenge for the vaccine industry.
When cases of the zoonotic infection monkeypox began occurring in countries where the virus is not usually found this year, it prompted concerns that we were headed for another COVID-19-type health emergency.
But, while the surge in non-endemic countries is unusual[i], monkey pox is unlikely to go global because its route of transmission appears to differ from SARS-CoV-2, says the World Health Organisation (WHO).
That said, the WHO is concerned about monkeypox[ii]. In June[iii], the Geneva-headquartered organisation called for 'intense response efforts' to control the spread of the virus.
These efforts should include 'ensuring vaccines, treatments and other tools are available to at-risk populations and shared fairly' according to WHO chief Tedros Adhanom Ghebreysus, who noted that until recently monkeypox was not a focus for industry.
'Monkeypox has been circulating in a number of African countries for decades and has been neglected in terms of research, attention and funding. This must change,' Ghebreysus said.
Vaccines
Current vaccination efforts are focused on products designed to protect against smallpox, based on the similarity of the viruses. According to the US Centers for Disease Control and Prevention (CDC) [iv], the 'smallpox vaccine is at least 85% effective in preventing monkeypox.'
In Europe[v], authorities have acquired 110,000 doses of Imvanex (also known as MVA-BN) - a smallpox vaccine made by Bavarian Nordic A/S – to allow for rapid containment of any monkeypox outbreaks.
In June[vi], Bavarian Nordic said it would complete the order in the next few months.
Imvanex contains a live modified form of the vaccinia virus called ‘vaccinia Ankara’, which is related to both the smallpox and monkeypox viruses.
In the US, Imvanex – which is sold as Jynneos – is authorised for the prevention of both smallpox and monkeypox. It is also approved in Canada, where it is sold as Imvamune.
In July, according to Bavarian Nordic[vii], the US Biomedical Advanced Research and Development Authority (BARDA) ordered 2.5 million Jynneos doses, having already bought three million doses in June. In total, the orders mean BARDA will have a stockpile of 7 million doses.
Bavarian Nordic said the additional order will be filled by an unnamed US CDMO using bulk vaccine already manufactured under previous contracts.
The Danish drug firm revised its financial guidance for 2022, citing the surge in Imvanex orders. It now expects revenue to be between DKK 2,700 and 2,900 million, though it previously predicted sales in the DKK 2,300 and 2,500 million range.
Other vaccines
In the US, a second vaccine called Acam2000 [viii] is also recommended by the CDC [ix] for people who may be exposed to orthopoxviruses, including monkeypox.
Acam2000 contains a live virus called vaccinia, which is a "pox"-type virus related to smallpox but causes milder disease. The vaccine was developed by Sanofi Pasteur, however it was acquired by Emergent Biosolutions in 2017[x].
A third smallpox vaccine called LC16 – made by Kumamoto, Japan-based KM Biologics – is also a potential option for preventing monkeypox infection according [xi]to the WHO.
The organisation wrote: 'For persons for whom replicating vaccines may be considered a precaution or are contraindicated, non-replicating (such as MVA-BN) or minimally replicating, such as LC16 vaccine should be used. This concerns persons with immune deficiencies, immunosuppression therapies or atopic dermatitis, as well as children and pregnant or breastfeeding women.'
The vaccine – which is an attenuated, replicating smallpox vaccine derived from the Lister strain of vaccinia - is the only smallpox vaccine licensed for use in Japan to prevent infection in children.
Supplies
The sudden surge in demand for vaccines that protect against monkeypox is stretching capacity to the limit. According to a WHO advisory in June, vaccine supply is 'very constrained.'
Concerns about supplies have already prompted some governments to restrict access. In the UK, for example, authorities [xii]have decided to give people one does of the MVA vaccine –rather than two recommended by Bavarian Nordic – in order to conserve stocks.
To address these supply issues, the WHO called on governments and manufacturers to work together to ensure supply is made available.
It said: 'Manufacturers are also encouraged to consider smallpox / monkeypox vaccine presentation and packaging to optimise operational features and reduce cold-chain requirements…Modern training materials should be developed and made available on accessible platforms for the use of bifurcated needles where required.'
Distribution of global monkeypox cases. Source: US Centers for Disease Control and Prevention
Vaccine candidates
Several other monkeypox-specific vaccines have entered development. For example[xiii], Moderna – the firm behind the COVID-19 jab Spikevax – said it is testing potential vaccines against monkeypox in pre-clinical trials.
Tonix Pharmaceuticals is also working on a jab. Last month, the firm shared preclinical data from a study of TNX-801, its monkeypox vaccine candidate.
And beyond vaccines, several therapeutics are already being tested. According to a study published in the Lancet in May [xiv] two oral drugs, brincidofovir and tecovirimat, have been approved for treatment of smallpox and have demonstrated efficacy against monkeypox in animals.
[iii] https://news.un.org/en/story/2022/06/1121362
[iv] https://www.cdc.gov/poxvirus/monkeypox/clinicians/smallpox-vaccine.html
[vi] https://www.bavarian-nordic.com/investor/news/news.aspx?news=6585
[vii] https://www.bavarian-nordic.com/investor/news/news.aspx?news=6591
[ix] https://www.cdc.gov/poxvirus/monkeypox/clinicians/smallpox-vaccine.html
[xi] https://apps.who.int/iris/rest/bitstreams/1433527/retrieve
[xiv] https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00228-6/fulltext
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Pharmapack 2024 - From the Floor
Paris once again welcomes Europe’s leading trade show in pharmaceutical packaging and drug delivery innovation. Join our content team as Pharmapack 2024 opens its doors to leading experts and innovators in pharmaceutical packaging and drug delive... -
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News CPHI Pharma Awards 2023 – API Development and Innovation Winners: Snapdragon Chemistry, a Cambrex Company
After another year of impressive nominations for the CPHI Pharma Awards our winners were announced at CPHI Barcelona in October. In this series of interviews, we speak to the teams behind the award-winning projects, concepts, and technologies. -
News PharmaKure gains authorisation for next stage testing on Alzheimer's treatment
Clinical stage pharmaceutical company PharmaKure gains permission from UK authorities to enter into further testing for PK051 for the treatment of patients with mild cognitive impairment associated with Alzheimer's disease. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News Navigating the Future: Challenges and Opportunities in Pharma Innovation and Investment – CPHI Barcelona 2023 Roundtable Report
In this comprehensive downloadable report, hear from a range of experts in finance and investment in the pharma industry on what investment trends will be shaping the future of the industry, in Catalonia, and the wider world. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance